News
ORIC
9.76
+3.28%
0.31
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts In Phase 1b Trial Of ORIC-114 In Patients With Mutated NSCLC
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR atypical mutations. Company expects to report updated Phase 1a data in the first half of 2025. The drug is being developed for the treatment of EGFR exon 20 cancer.
Benzinga · 2d ago
ORIC PHARMACEUTICALS INC - EXPECT TO REPORT UPDATED PHASE 1B DATA IN FIRST HALF OF 2025
Reuters · 2d ago
Weekly Report: what happened at ORIC last week (0408-0412)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
TipRanks · 04/09 11:40
ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2024 AACR Annual Meeting
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life. ORIC-613, a potential first- and best-in-class selective PLK4 inhibitor, will be presented at the 2024 American Association for Cancer Research Annual Meeting. ORIC Pharmaceuticals, Inc. Is a company focused on developing treatments for cancer.
Benzinga · 04/08 12:15
Weekly Report: what happened at ORIC last week (0401-0405)?
Weekly Report · 04/08 09:23
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Management will participate in the following investor conferences in April. ORIC Pharmaceuticals, Inc. Is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. The company will be in San Francisco and San Diego in April to participate in investor conferences.
Barchart · 04/04 15:30
Weekly Report: what happened at ORIC last week (0325-0329)?
Weekly Report · 04/01 09:22
Oric Pharmaceuticals Bolsters Incentive Plan to Attract Talent
ORIC Pharmaceuticals adds 650,000 shares to its 2022 Equity Incentive Plan. The company has 1.15 million shares available for equity awards to new hires. The move aligns with Nasdaq Listing Rules without stockholder approval. The plan mirrors the company's 2020 equity incentive plan.
TipRanks · 03/29 20:33
ORIC Pharmaceuticals: Rally Seems Overdone
ORIC Pharmaceuticals, Inc. Has three programs in the clinic. The company focuses on developing therapies to counter resistance mechanisms in cancer. ORIC's stock has seen significant gains since releasing promising data from its ORIC-114 program. The brain-penetrant candidate induced multiple partial responses in NSCLC patients. The firm has a strong balance sheet with approximately $350 million in cash.
Seeking Alpha · 03/29 09:29
Oric Pharmaceuticals Price Target Cut to $18.00/Share From $19.00 by JP Morgan
Dow Jones · 03/27 14:51
Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 03/27 14:51
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $18
Benzinga · 03/27 14:40
Weekly Report: what happened at ORIC last week (0318-0322)?
Weekly Report · 03/25 09:23
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Rosenblatt boosted the price target for Micron Technology, Inc. (NASDAQ:MU) from $140 to $225 on Wednesday. TD Cowen raised the pricetarget for Broadcom Inc. From $1,400 to $1.5 million. Needham increased the price targets for Alight and Crocs. Five Below shares gained 1.1%.
Benzinga · 03/21 13:15
Oric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming Catalysts
TipRanks · 03/21 10:27
Oric Pharmaceuticals Price Target Raised to $21.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 03/21 10:25
Oric Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/21 10:25
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $21
Benzinga · 03/21 10:15
Weekly Report: what happened at ORIC last week (0311-0315)?
Weekly Report · 03/18 09:23
More
Webull provides a variety of real-time ORIC stock news. You can receive the latest news about Oric Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.